Imaging agents:
Indications for: ABLAVAR
For use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
Adult Dosage:
Give as IV bolus inj over 30 seconds followed by 25–30mL normal saline flush. 0.12mL/kg (0.03mmol/kg). See full labeling for imaging guidelines.
Children Dosage:
<18yrs: not established.
ABLAVAR Warnings/Precautions:
Chronic, severe kidney disease (GFR<30mL/min/1.73m2), acute kidney injury: increased risk of nephrogenic systemic fibrosis; avoid unless necessary, allow sufficient period of time for elimination prior to re-administration. Screen for acute kidney injury and other conditions that reduce renal function (eg, >60yrs, hypertension, diabetes). Anaphylactoid reaction possible (may be fatal); discontinue immediately if occurs; have emergency resuscitative equipment available. History of drug reactions, asthma, allergy or other hypersensitivity disorders. Risk of QTc prolongation; consider obtaining baseline ECG to assess risk, consider follow up ECG and risk reduction measures until contrast agent eliminated. Pregnancy (Cat.C). Nursing mothers.
ABLAVAR Classification:
Gadolinium-based contrast agent.
ABLAVAR Interactions:
Caution with concomitant drugs that bind to albumin.
Adverse Reactions:
Pruritus, headache, nausea, vasodilation, paresthesia, inj site bruising, dysgeusia, burning sensation, venipuncture site bruise, hypertension, dizziness, feeling cold; hypersensitivity reactions.
How Supplied:
Single-use vials (10mL, 15mL)—10
